Published in Biochem Biophys Res Commun on June 10, 2005
A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo. Cell Rep (2013) 1.67
TP53 mutations in nonsmall cell lung cancer. J Biomed Biotechnol (2011) 1.46
Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH. Small (2008) 1.31
MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother Pharmacol (2009) 1.13
Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis. BMC Cancer (2012) 0.98
Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma. BMC Cancer (2009) 0.96
Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment. BMC Cancer (2010) 0.90
Disparate chromatin landscapes and kinetics of inactivation impact differential regulation of p53 target genes. Cell Cycle (2010) 0.89
Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology. Chin J Cancer (2012) 0.85
Type I insulin-like growth factor receptor induces pulmonary tumorigenesis. Neoplasia (2009) 0.84
Accurate DNA fragment sizing by capillary electrophoresis with laser-induced fluorescence array for detection of sequence specificity of DNA damage. Anal Chem (2008) 0.80
Drug resistance in lung cancer. Lung Cancer (Auckl) (2010) 0.80
Unique roles of Akt1 and Akt2 in IGF-IR mediated lung tumorigenesis. Oncotarget (2016) 0.78
Scriptaid overcomes hypoxia-induced cisplatin resistance in both wild-type and mutant p53 lung cancer cells. Oncotarget (2016) 0.78
The role of mitochondria in the development and progression of lung cancer. Comput Struct Biotechnol J (2013) 0.78
Mutation Analysis of TP53 Tumor Suppressor Gene in Colorectal Cancer in Patients from Iran (Kerman Province). Iran J Basic Med Sci (2012) 0.76
Zinc supplementation induces apoptosis and enhances antitumor efficacy of docetaxel in non-small-cell lung cancer. Drug Des Devel Ther (2015) 0.76
In vitro study on apoptosis induced by strontium-89 in human breast carcinoma cell line. J Biomed Biotechnol (2011) 0.75
Epigenetic reduction of DNA repair in progression to gastrointestinal cancer. World J Gastrointest Oncol (2015) 0.75
A non-surgical method for induction of lung cancer in Wistar rats using a combination of NNK and high dietary fats. Protoplasma (2013) 0.75
p53-independent structure-activity relationships of 3-ring mesogenic compounds' activity as cytotoxic effects against human non-small cell lung cancer lines. BMC Cancer (2016) 0.75
Distal airway epithelial progenitor cells are radiosensitive to High-LET radiation. Sci Rep (2016) 0.75
Oncogenes do not Fully Override Cell-intrinsic Traits: Pronounced Impact of the Cellular Programme. Cancer Microenviron (2009) 0.75
Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol (2008) 3.95
Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol (2009) 3.66
Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys (2012) 2.80
The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer (2003) 1.96
Essential role for DNA-PK-mediated phosphorylation of NR4A nuclear orphan receptors in DNA double-strand break repair. Genes Dev (2011) 1.60
Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol (2006) 1.29
Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer (2009) 1.24
Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. Radiother Oncol (2008) 1.20
Mitochondrial dysfunction is an essential step for killing of non-small cell lung carcinomas resistant to conventional treatment. Oncogene (2002) 1.20
Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol (2005) 1.16
Metabolomics: moving to the clinic. J Neuroimmune Pharmacol (2009) 1.15
An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells. Mol Cancer Res (2008) 1.14
Long-term incidence of hypothyroidism after radiotherapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys (2004) 1.10
Toxicity after reirradiation of pulmonary tumours with stereotactic body radiotherapy. Radiother Oncol (2011) 1.08
Affinity prefractionation for MS-based plasma proteomics. Proteomics (2009) 1.07
Evaluation of three principally different intact protein prefractionation methods for plasma biomarker discovery. J Proteome Res (2008) 1.05
Heat shock proteins 27, 60 and 70 as prognostic markers of prostate cancer. APMIS (2008) 0.99
Up-regulation, modification, and translocation of S100A6 induced by exposure to ionizing radiation revealed by proteomics profiling. Mol Cell Proteomics (2007) 0.98
Use of narrow-range peptide IEF to improve detection of lung adenocarcinoma markers in plasma and pleural effusion. Proteomics (2009) 0.97
Lung cancer proteomics, clinical and technological considerations. J Proteomics (2010) 0.94
Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel. Crit Rev Oncol Hematol (2007) 0.92
Expression of inhibitor of apoptosis proteins in small- and non-small-cell lung carcinoma cells. Exp Cell Res (2002) 0.91
Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer. Lung Cancer (2008) 0.91
Validation of the 7th TNM classification for non-small cell lung cancer: a retrospective analysis on prognostic implications for operated node-negative cases. Acta Oncol (2012) 0.91
Multidrug resistance in relapsed acute myeloid leukemia: evidence of biological heterogeneity. Cancer (2013) 0.90
NTCP modelling of lung toxicity after SBRT comparing the universal survival curve and the linear quadratic model for fractionation correction. Acta Oncol (2011) 0.90
Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology. Lung Cancer (2012) 0.90
Expression of Ku86 confers favorable outcome of tonsillar carcinoma treated with radiotherapy. Head Neck (2003) 0.90
In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. Clin Cancer Res (2013) 0.89
Apoptotic pathways and therapy resistance in human malignancies. Adv Cancer Res (2005) 0.89
Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor. J Proteome Res (2011) 0.89
Proteomic data analysis workflow for discovery of candidate biomarker peaks predictive of clinical outcome for patients with acute myeloid leukemia. J Proteome Res (2008) 0.88
Quantitative proteomics profiling of primary lung adenocarcinoma tumors reveals functional perturbations in tumor metabolism. J Proteome Res (2013) 0.88
Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo. Invest New Drugs (2004) 0.88
miRNA-214 is related to invasiveness of human non-small cell lung cancer and directly regulates alpha protein kinase 2 expression. Genes Chromosomes Cancer (2013) 0.87
Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer. Eur J Cancer (2010) 0.86
Biological effective dose evaluation and assessment of rectal and bladder complications for cervical cancer treated with radiotherapy and surgery. J Contemp Brachytherapy (2012) 0.86
Modulation of response to radiation of human lung cancer cells following insulin-like growth factor 1 receptor inactivation. Cancer Lett (2004) 0.86
The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo. Mol Cancer Ther (2007) 0.85
The antipsychotic drug trifluoperazine inhibits DNA repair and sensitizes non small cell lung carcinoma cells to DNA double-strand break induced cell death. Mol Cancer Ther (2007) 0.85
Different G2/M accumulation in M059J and M059K cells after exposure to DNA double-strand break-inducing agents. Int J Radiat Oncol Biol Phys (2005) 0.85
Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1. J Drug Target (2003) 0.85
Expression of PDX-1 in prostate cancer, prostatic intraepithelial neoplasia and benign prostatic tissue. APMIS (2008) 0.84
The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan. Biochem Pharmacol (2010) 0.84
Defective stress kinase and Bak activation in response to ionizing radiation but not cisplatin in a non-small cell lung carcinoma cell line. Exp Cell Res (2003) 0.84
Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester): comparison with melphalan. Anticancer Drugs (2003) 0.84
Dual targeting of IGF-1R and PDGFR inhibits proliferation in high-grade gliomas cells and induces radiosensitivity in JNK-1 expressing cells. J Neurooncol (2007) 0.83
Robustness and accuracy of high speed LC-MS separations for global peptide quantitation and biomarker discovery. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 0.82
Pre-fractionation of archival frozen tumours for proteomics applications. J Biotechnol (2006) 0.82
Growth factor receptors signaling in glioblastoma cells: therapeutic implications. J Neurooncol (2008) 0.82
Rad51-related changes in global gene expression. Biochem Biophys Res Commun (2006) 0.81
APS8, a polymeric alkylpyridinium salt blocks α7 nAChR and induces apoptosis in non-small cell lung carcinoma. Mar Drugs (2013) 0.81
Comparison of three approaches for inhibiting insulin-like growth factor I receptor and their effects on NSCLC cell lines in vitro. Growth Factors (2007) 0.81
Proteomics and pathway analysis identifies JNK signaling as critical for high linear energy transfer radiation-induced apoptosis in non-small lung cancer cells. Mol Cell Proteomics (2009) 0.81
PKC 412 sensitizes U1810 non-small cell lung cancer cells to DNA damage. Exp Cell Res (2005) 0.80
RasGTPase-activating protein is a target of caspases in spontaneous apoptosis of lung carcinoma cells and in response to etoposide. Carcinogenesis (2004) 0.80
Antitumor activity of the novel melphalan containing tripeptide J3 (L-prolyl-L-melphalanyl-p-L-fluorophenylalanine ethyl ester): comparison with its m-L-sarcolysin analogue P2. Mol Cancer Ther (2003) 0.79
p53 is involved in clearance of ionizing radiation-induced RAD51 foci in a human colon cancer cell line. Biochem Biophys Res Commun (2006) 0.79
Pemetrexed in second-line treatment of non-small-cell lung cancer. Oncology (Williston Park) (2004) 0.79
Annotated regions of significance of SELDI-TOF-MS spectra for detecting protein biomarkers. Proteomics (2006) 0.79
Endogenously released Smac is insufficient to mediate cell death of human lung carcinoma in response to etoposide. Exp Cell Res (2004) 0.79
Apoptotic signaling pathways in lung cancer. J Thorac Oncol (2007) 0.78
Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML. Exp Hematol (2009) 0.78
A novel method for sample preparation of fresh lung cancer tissue for proteomics analysis by tumor cell enrichment and removal of blood contaminants. Proteome Sci (2010) 0.78
Expression of DNA-PKcs and Ku86, but not Ku70, differs between lymphoid malignancies. Exp Mol Pathol (2004) 0.78
Synthesis and cytotoxicity of the dihydrated complex of oxaliplatin. Cancer Lett (2002) 0.78
Structure-activity relationship for alkylating dipeptide nitrogen mustard derivatives. Oncol Res (2003) 0.77
Heat shock protein 72 does not modulate ionizing radiation-induced apoptosis in U1810 non-small cell lung carcinoma cells. Cancer Biol Ther (2003) 0.77
Long-term results of a prospective phase II trial of medically inoperable stage I NSCLC treated with SBRT - the Nordic experience. Acta Oncol (2015) 0.76
Phosphoprotein analysis reveals MEK inhibition as a way to target non-small cell lung cancer tumor initiating cells. Int J Radiat Biol (2014) 0.76
Radiation-induced cell cycle response in lymphocytes is not related to clinical side-effects in breast cancer patients. Anticancer Res (2003) 0.76
Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours. J Transl Med (2012) 0.76
A role for Myh1 in DNA repair after treatment with strand-breaking and crosslinking chemotherapeutic agents. Environ Mol Mutagen (2013) 0.75
X-ray-induced DNA double-strand breaks in mouse l1210 cells: a new computational method for analyzing neutral filter elution data. Radiat Res (2003) 0.75
Clinical activity of sorafenib in a previously treated advanced urothelial cancer patient. Anticancer Drugs (2013) 0.75
Evaluation of spectral karyotyping (SKY) in biodosimetry for the triage situation following gamma irradiation. Int J Radiat Biol (2006) 0.75
Dummy run for a phase II study of stereotactic body radiotherapy of T1-T2 N0M0 medical inoperable non-small cell lung cancer. Acta Oncol (2006) 0.75
[The role of adjuvant chemotherapy in the treatment of early stage NSCLC after radical surgery]. Suppl Tumori (2004) 0.75
Second-line treatment options in non-small cell lung cancer: a comparison of cytotoxic agents and targeted therapies. Semin Oncol (2006) 0.75
Neoadjuvant strategies for non-small cell lung cancer. Suppl Tumori (2004) 0.75